ERBB2 and breast cancer: Twenty-five (25) out of the 70 breast cancer patients representing 35.7% were diagnosed with luminal B. The second most frequent subtype was the triple-negative subtype (25.7%) followed by HER2 enriched subtype (21.4%) and then Normal-like breast cancer 9 (12.9%).